Filing Flows › Companies › Amneal Pharmaceuticals › Timeline
Amneal Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+72.9% to $20.14
Amneal Pharmaceuticals (AMRX) stock rose 73% over the last 252 sessions, to $20.14. On the way it reported 4 quarters, its insiders filed 7 open-market trades and 4 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 3, 2026 | Earnings | Earnings: beat the EPS estimate by 9.5% | −1.1% (−1.4% vs SPY) | — | — |
| Aug 13, 2026 | Form 144 | Form 144: John Kiely plans to sell $880K | −2.2% (−2.9% vs SPY) | +2.5% (+3.0% vs SPY) | −3.8% (−2.7% vs SPY) |
| Aug 13, 2026 | Insider sale | Kiely John sold $882K | −2.2% (−2.9% vs SPY) | +2.5% (+3.0% vs SPY) | −3.8% (−2.7% vs SPY) |
| Aug 12, 2026 | Form 144 | Form 144: Nikita Shah plans to sell $2.6M | +3.2% (+3.0% vs SPY) | +6.2% (+6.6% vs SPY) | −1.4% (+0.3% vs SPY) |
| Aug 12, 2026 | Insider sale | Shah Nikita sold $2.6M | +3.2% (+3.0% vs SPY) | +6.2% (+6.6% vs SPY) | −1.4% (+0.3% vs SPY) |
| Aug 12, 2026 | Insider sale | Daly Jason B. sold $3.7M | +3.2% (+3.0% vs SPY) | +6.2% (+6.6% vs SPY) | −1.4% (+0.3% vs SPY) |
| Aug 11, 2026 | Form 144 | Form 144: J Kevin Buchi plans to sell $2.9M | −4.5% (−4.1% vs SPY) | +3.0% (+3.0% vs SPY) | −3.6% (−2.2% vs SPY) |
| Aug 11, 2026 | Form 144 | Form 144: Jason Daly plans to sell $3.6M | −4.5% (−4.1% vs SPY) | +3.0% (+3.0% vs SPY) | −3.6% (−2.2% vs SPY) |
| Aug 11, 2026 | Insider sale | Daly Jason B. sold $117K | −4.5% (−4.1% vs SPY) | +3.0% (+3.0% vs SPY) | −3.6% (−2.2% vs SPY) |
| Aug 10, 2026 | 8-K | Material definitive agreement | −4.5% (−4.1% vs SPY) | +3.0% (+3.0% vs SPY) | −3.6% (−2.2% vs SPY) |
| Aug 3, 2026 | 8-K | Material definitive agreement | −2.0% (−3.8% vs SPY) | −5.3% (−7.3% vs SPY) | −6.4% (−7.0% vs SPY) |
| Jul 30, 2026 | Earnings | Earnings: beat the EPS estimate by 30.3% | −3.2% (−4.8% vs SPY) | −3.4% (−8.8% vs SPY) | −5.9% (−11.4% vs SPY) |
| May 11, 2026 | Insider sale | Autor Deborah M. sold $451K | −3.2% (−3.5% vs SPY) | −10.1% (−10.3% vs SPY) | +10.7% (+10.7% vs SPY) |
| May 7, 2026 | Earnings | Earnings: beat the EPS estimate by 59.6% | +0.7% (+1.0% vs SPY) | −9.5% (−10.6% vs SPY) | +1.0% (+0.4% vs SPY) |
| Apr 22, 2026 | 8-K | Material definitive agreement | −1.5% (−2.6% vs SPY) | −2.2% (−3.3% vs SPY) | −6.2% (−11.4% vs SPY) |
| Feb 27, 2026 | Earnings | Earnings: beat the EPS estimate by 14.1% | −4.8% (−4.3% vs SPY) | −8.9% (−7.7% vs SPY) | −20.1% (−12.0% vs SPY) |
| Feb 3, 2026 | 8-K | Material definitive agreement | +1.3% (+1.8% vs SPY) | +3.5% (+3.2% vs SPY) | −7.2% (−6.0% vs SPY) |
| Nov 17, 2025 | Insider sale | Nark Ted C sold $586K | −0.5% (+0.4% vs SPY) | +2.6% (+4.6% vs SPY) | +4.5% (+3.4% vs SPY) |
| Nov 12, 2025 | Insider sale | Shah Nikita sold $1.6M | −0.4% (−0.5% vs SPY) | −3.2% (+0.2% vs SPY) | +2.5% (+1.6% vs SPY) |
Insiders’ record here
In the year on the chart, Amneal Pharmaceuticals' insiders reported 0 open-market buys ($0) and 7 sales ($9.8M). Of the 3 old enough to score, 0 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale +24.8%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 2.01 Completed acquisition or disposition | 2,671 | +0.1% | 52% | +1.2% | ±1.6% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Amneal Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.